Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Recent And Upcoming FDA Advisory Committees

Executive Summary

Recent and upcoming FDA advisory committee meetings and a summary of topics covered.

You may also be interested in...



Allergan’s Nasal Spray For Frequent Nighttime Urination Gets Cautious Panel Nod

Desmopressin's limited efficacy over placebo doesn't dissuade FDA's advisory committee, which votes 14 to 4 in favor of approval even as many suggest indication be narrowed.

Cempra's Solithromycin On Track To Enter Generic, But Resistant, CABP Market

FDA schedules November advisory committee for Cempra's first-in-class antibiotic for community-acquired bacterial pneumonia.

Bausch + Lomb Rings Bell On 'Largest' Launch Year

Canadian firm’s eye health supplements Occuvite and PreserVision remain top sellers, with ReNu and Biotrue contact lens solutions and Lumify eye drops and skin care line rounding out its top 10 revenue generators.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS119374

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel